The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Open accessPublished version of a preprint
Abstract
Abstract Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing development in patients with advanced solid tumors and lymphoma. Experimental Design: A total of 346 patients with advanced cancers who had progressed after standard treatment received at least one dose of urelumab in one of three dose–escalation, monotherapy studies. Urelumab was administered at doses ranging from 0.1 to 15 mg/kg. Safety analyses included treatment-related and serious adverse events (AEs), as well as treatment-related AEs leading to discontinuation and death, with a focus on liver function test abnormalities and hepatic AEs. Results: Urelumab doses between 1 and 15 mg/kg given every 3 weeks resulted in a higher frequency of treatment-related AEs than 0.1 or 0.3 mg/kg every 3 weeks. Dose was the single most important factor contributing to transaminitis development, which was more frequent and severe at doses ≥1 mg/kg. At the MTD of 0.1 mg/kg every 3 weeks, urelumab was relatively well tolerated, with fatigue (16%) and nausea (13%) being the most common treatment-related AEs, and was associated with immunologic and pharmacodynamic activity demonstrated by the induction of IFN-inducible genes and cytokines. Conclusions: Integrated evaluation of urelumab safety data showed significant transaminitis was strongly associated with doses of ≥1 mg/kg. However, urelumab 0.1 mg/kg every 3 weeks was demonstrated to be safe, with pharmacodynamic activity supporting continued clinical evaluation of this dose as monotherapy and in combination with other immuno-oncology agents. Clin Cancer Res; 23(8); 1929–36. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, phase I studies with CD137-directed mAb urelumab caused significant elevation of liver enzymes (211), and a second anti-CD137 antibody, utomilumab, was well tolerated but had limited efficacy (212).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301945 · Cited by 205
RetractedTargeting CD137 enhances the efficacy of cetuximab
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73014 · Cited by 160
RetractedSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationImmune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141 · cited 3×
“Leukopenia, n (%) Total grade 1–4 10 (33) 19 (34) 84 (37) Grade 1 13 (21) 8 (14) 50 (22) Grade 2 2 (3) 5 (9) 15 (7) Grade 3 4 (7) 4 (7) 14 (6) Grade 4 1 (2) 2 (4) 5 (2)”
Self-citationMonoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellström, K. E., Mittler, R. S., & Chen, L. (1997) · Nature Medicine · doi:10.1038/nm0697-682 · Cited by 898
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 346
Sznol, M., Hodi, F. S., Margolin, K., McDermott, D. F., Ernstoff, M. S., Kirkwood, J. M., Wojtaszek, C., Feltquate, D., & Logan, T. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3007 · Cited by 204
Kocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2128 · Cited by 177
Research works printed but not linked: 1
- Jure-Kunkel, 2006, Functional characterization of fully human anti-CD137 antibodies
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
NK cells for cancer immunotherapy
Shimasaki, N., Jain, A., & Campana, D. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0052-1 · Cited by 1,222
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0582-8 · Cited by 804
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
Metadata
- Authors
- Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M., & Levy, R.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Clinica Universidad de Navarra (ES)
- Angeles Clinic and Research Institute (US)
- Aarhus University Hospital (DK)
- Institut Gustave Roussy (FR)
- 9Istituto Oncologico Veneto, Padua, Italy.
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- University of Siena (IT)
- Providence Portland Medical Center (US)
- Abramson Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- 14Bristol-Myers Squibb, Princeton, New Jersey.
- Stanford Medicine (US)
- Yale Cancer Center (US)
- Corresponding author
- Levy, Ronald
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2017-04-13
- Volume
- 23
- Issue
- 8
- Pages
- 1929-1936
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2537734913
- Cited by
- 424
- References
- 24
- Citations by year
- 2026: 35 · 2025: 40 · 2024: 41 · 2023: 60 · 2022: 48 · 2021: 64 · 2020: 45 · 2019: 37 · 2018: 31 · 2017: 20
- FWCI
- 15.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- urelumab, anti-CD137 monoclonal antibody, dose escalation, maximum tolerated dose, elevated liver enzymes, hepatotoxicity, liver function tests, treatment-related adverse events, fatigue, nausea, cytokines, immunotherapy, advanced solid tumors, lymphoma
- MeSH terms
- Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Melanoma, Middle Aged, Neoplasms, Maximum Tolerated Dose, 4-1BB Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1272
- The paper
- Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M., & Levy, R. (2017). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.